BMS to invest in, collaborate with Compugen

Oct. 12, 2018

Bristol-Myers Squibb and Israel-based Compugen said they will collaborate in clinical trials for patients with advanced solid tumors.

The trials will evaluate the safety and tolerability of Compugen’s COM701, an investigational antibody, in combination with BMS’ immune checkpoint inhibitor, Opdivo.

Additionally, Bristol-Myers Squibb will invest $12 million in Compugen, purchasing 2,424,243 shares — a 4.1 percent stake.

Read the press release